325 related articles for article (PubMed ID: 24938378)
1. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z; Wang Z
Int J Hematol; 2014 Jul; 100(1):38-50. PubMed ID: 24938378
[TBL] [Abstract][Full Text] [Related]
2. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
3. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
4. What is the standard regimen for patients with acute promyelocytic leukemia?
Lo-Coco F; Cicconi L
Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
6. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121
[TBL] [Abstract][Full Text] [Related]
7. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
9. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
11. How to manage acute promyelocytic leukemia.
Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
[TBL] [Abstract][Full Text] [Related]
12. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Look AT
J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
[No Abstract] [Full Text] [Related]
13. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
[TBL] [Abstract][Full Text] [Related]
14. ATRA plus arsenic gets another "A" in APL.
Park JH
Blood; 2012 Aug; 120(8):1535-6. PubMed ID: 22918418
[TBL] [Abstract][Full Text] [Related]
15. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
16. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Park JH; Tallman MS
Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
[TBL] [Abstract][Full Text] [Related]
18. Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Mikoshiba M; Ohashi K; Takei N; Okuyama Y; Maeda Y; Hiruma K; Akiyama H; Fukuhara O; Takeshita A; Sakamaki H
Int J Hematol; 2002 Jan; 75(1):104-6. PubMed ID: 11843281
[No Abstract] [Full Text] [Related]
19. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
20. Current treatment strategy of acute promyelocytic leukemia.
Mi J
Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
